Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.
In preclinical drug discovery, the identification of potential drug candidates requires a thorough evaluation of their pharmacological effects, as well as any potential off-target liabilities. Nuclear receptors play a crucial role in many physiological processes and have emerged as important targets for drug discovery. However, potential drugs often have multiple effects, often within a gene family, leading to potential polypharmacology, where new beneficial effects, as well as off-target liabilities, can be discovered.
To triage or prioritize data, dose-response experiments with nuclear receptor assays can be used. In this presentation, we discuss the use of cell-based reporter assays for nuclear receptor profiling and how this strategy can help identify potential drug candidates with desirable pharmacological properties and reduced off-target effects.
Key Topics Include:
- Understand the principles and advantages of using cell-based reporter assays for nuclear receptor profiling, including the ability to evaluate the potency, selectivity, and potential off-target effects of drug candidates
- Learn about the different types of cell-based assays that can be used to triage compounds in the drug discovery pipeline with safety liabilities
- Discover how nuclear receptor profiling can help identify potential drug candidates with desirable pharmacological properties
Presenters
Professor
Veterinary and Biomedical Sciences
Penn State University
Production Partner
INDIGO Biosciences
